U.S. Markets closed

Edesa Biotech, Inc. (EDSA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.97+0.39 (+5.15%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.58
Bid7.92 x 800
Ask7.95 x 900
Day's Range7.09 - 8.02
52 Week Range1.58 - 19.10
Avg. Volume1,814,439
Market Cap70.608M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.73
Earnings DateAug 13, 2020 - Aug 15, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.00

    Edesa Biotech Files IND Application for Phase 2/3 COVID-19 Study

    TORONTO, ON / ACCESSWIRE / July 30, 2020 / Edesa Biotech, Inc.


    Edesa Biotech Receives Regulatory Approval to Initiate COVID-19 Study

    TORONTO, ON / ACCESSWIRE / June 15, 2020 / Edesa Biotech, Inc. (EDSA), a clinical-stage biopharmaceutical company, has received expedited approval from Health Canada to begin a Phase 2/3 clinical study of its investigational drug, EB05, which the company is developing as a potential treatment for moderate to severe COVID-19 patients. The company reported that it has EB05 drug product available now and is seeking government grants to accelerate the initiation and rollout of the study, beginning at up to 30 sites. Based on previous clinical data and the mechanism of action, the company believes that modulating this well understood signaling pathway could reduce the number of ICU patients and intubation/ventilation procedures, ultimately saving lives.

  • EDSA: Interim Analysis of Phase 2b Trial of EB01 in second half of 2020…
    Zacks Small Cap Research

    EDSA: Interim Analysis of Phase 2b Trial of EB01 in second half of 2020…

    By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Update on Phase 2b Trial of EB01 Edesa Biotech, Inc. (NASDAQ:EDSA) is currently conducting a Phase 2b clinical trial of EB01 2.0% cream in patients with ACD. The randomized, double blind, placebo controlled, sample size adaptive design trial is expected to enroll approximately 46 patients in Part A randomized 1:1